Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 17,854 matching trials from the live ClinicalTrials.gov search.
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Metastatic Melanoma
Interventions
VCL-IM01 (encoding IL-2) with Electroporation
Genetic
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Conditions
Acute Schizophrenia
Interventions
OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 12 more
Conditions
Chronic Graft-versus-host Disease
Interventions
Itacitinib, Placebo, Methylprednisolone, Prednisone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
Conditions
Fanconi Anemia
Interventions
JSP191, CliniMACS Prodigy System, Depleted Stem Cell Transplant, Rabbit Anti-Thymoglobulin (rATG), Cyclophosphamide, Fludarabine, Rituximab
Drug · Device · Biological
Lead sponsor
Porteus, Matthew, MD
Other
Eligibility
2 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Terminated Phase 2 Interventional Results available

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692
Conditions
Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Hepatocellular Carcinoma
Interventions
Technetium-99m macroaggregated albumin (Tc-99m MAA)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
6 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Head and Neck Cancer
Interventions
Medpulser Electroporation with Bleomycin
Combination Product
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Diego, California
Conditions
Breast Cancer, Breast Cancer Surgery
Interventions
Positron Emission Mammography (PEM)
Device
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Seattle, Washington
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

NCT04674306
Conditions
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Interventions
α-lactalbumin vaccine, Zymosan
Biological
Lead sponsor
George T. Budd
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Hydroxychloroquine, Bevacizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Imperial, California • Lakewood, California • Long Beach, California + 21 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

CharacterIzation of Adult Onset Autoimmune Diabetes

NCT03971955
Conditions
Diabetes
Interventions
Mixed Meal Test, Dual Energy X-Ray Absorptiometry (DEXA), Adipose Tissue Biopsy
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

NCT00618709
Conditions
Healthy
Interventions
ATX-101
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
Completed No phase listed Observational Accepts healthy volunteers

Assessing Urinary Hormones in Female Cancer Survivors

NCT03197532
Conditions
Effects of Chemotherapy
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hyperphagia in Prader-Willi Syndrome
Interventions
FE 992097, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Gainesville, Florida • Mineola, New York • Nashville, Tennessee
Completed Phase 1 Interventional Results available

Phase I Biomarker Study (BMS-936558)

NCT01358721
Conditions
Renal Cell Carcinoma
Interventions
BMS-936558 (Anti-PD-1)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Tampa, Florida + 8 more
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
Conditions
Hematologic Malignancies
Interventions
Pegfilgrastim
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Docetaxel, Gemcitabine
Drug
Lead sponsor
Tony Bekaii-Saab
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Conditions
Healthy Volunteer
Interventions
Placebo, RO4917838, diazepam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah